GORE TO HIGHLIGHT NEW CLINICAL EVIDENCE AND VASCULAR INNOVATIONS AT VEITHsymposium

Clinical presentations will feature advancements in aortic care and venous disease, alongside the introduction of the GORE^® GUIDRA Steerable Sheath

FLAGSTAFF, Ariz., Nov. 10, 2026 /PRNewswire/ -- W. L. Gore & Associates' medical business (Gore) will put its innovations and clinical evidence on full display at VEITHsymposium (VEITH), taking place Nov. 17-21, 2026, in New York City. From recent advances in complex aortic aneurysm repair to innovations in deep venous disease, Gore will highlight new clinical evidence and technologies across its vascular portfolio while connecting with physicians and the broader vascular community.

"VEITH is one of the most important gatherings of the vascular community, and this year's meeting comes at an exciting time for Gore," said Jason Belzer, Gore Americas Business Leader. "We are building on momentum across our vascular portfolio, including a recent FDA approval for an expanded indication of the GORE^® VIABAHN^® VBX Balloon Expandable Endoprosthesis and the launch of the GORE^® VIABAHN^® FORTEGRA Venous Stent. We are excited to share our progress, exchange ideas with physicians and continue advancing the field together."

Highlights of Gore's planned activities at VEITH include:

• Three-year outcomes in FEVAR and BEVAR

An expert discussion of three-year clinical outcomes from the EMBRACE Registry will be featured during a Gore-sponsored symposium with Luca Bertoglio, M.D., and Gustavo S. Oderich, M.D., on Thursday, Nov. 19, at noon. The discussion will move beyond headline results to explore the clinical lessons behind the data and what they mean for complex aortic care. EMBRACE evaluated the GORE^® VIABAHN^® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) as a bridging stent graft in fenestrated and branched endovascular aortic repair (FEVAR and BEVAR). The device recently received FDA approval for an expanded indication in the U.S.

• Expanding the evidence for deep venous disease

Professor Stephen Black will present one-year outcomes from the full 112-patient clinical study population evaluating the GORE^® VIABAHN^® FORTEGRA Venous Stent on Friday, Nov. 20, at 8:47 a.m. The prospective, international, multicenter study focuses on patients with symptomatic inferior vena cava obstruction, a complex condition for which clinical evidence has historically been limited. One-year clinical outcomes from the initial 89-patient cohort were recently published in the European Journal of Vascular and Endovascular Surgery. On Friday at noon, Professor Black and Kathleen Gibson, M.D., will share their expertise during the Gore-sponsored symposium exploring the evolution of venous stenting, from clinical need to purpose-built innovation.

• New steerable sheath launch

Gore will also introduce the GORE^® GUIDRA Steerable Sheath at VEITH, expanding its portfolio to help physicians address complex endovascular procedures. This new steerable sheath is designed to facilitate access and delivery of diagnostic or therapeutic devices in the vasculature. The initial launch will feature a 12 Fr size, with additional sizes planned for 2027.

• Roundtable on branched aortic repair

Jason Lee, M.D., and Shahab Toursavadkohi, M.D., will host a roundtable discussion on best practices in thoracoabdominal repair featuring the GORE^® EXCLUDER^® Thoracoabdominal Branch Endoprosthesis (TAMBE). The physicians will also discuss the newly published 30-day outcomes from the TAMBE post-approval study in the Journal of Vascular Surgery. The roundtable will take place during Gore's sponsored lunch symposium, "From Material Innovation to Clinical Performance: Advancing Branched Aortic Repair," on Nov. 17. Dr. Lee and Jonathan Bath, M.D., will also share their experience with TAMBE during scientific presentations.

• Advancing aortic arch therapy

Nimesh D. Desai, M.D., Ph.D., will discuss open surgical Zone 2 arch repair utilizing a sequential TEVAR approach with the GORE^® TAG^® Thoracic Branch Endoprosthesis (TBE). The presentation is part of Gore's sponsored lunch symposium, "Advancing Aortic Arch Therapy: Contemporary Techniques and Early Clinical Evidence," on Nov. 18.

• Materials science behind Gore innovation

For more than 50 years, Gore's materials science expertise has fueled innovation across its medical device portfolio. At VEITH, attendees will have an opportunity to explore how Gore applies its understanding of materials to develop technologies that address complex clinical challenges. A dedicated on-site experience will bring that expertise to life.

Scientific Presentations on Research into Therapies for the Aortic Arch and Ascending Aorta

CAUTION: Investigational device. Limited by United States law to investigational use.

Investigators will also present ongoing research in two areas of aortic care:

• Multibranch Arch Technology: Sukgu Han, M.D., will present on the prospective early feasibility evaluation of Gore's investigational multibranch arch (MBA) technology during Gore's sponsored lunch symposium on Nov. 18, marking its first presentation at a scientific meeting.

• ARISE Pivotal Trials: Ali Azizzadeh, M.D., will share insights from ongoing clinical research into the endovascular treatment of the ascending aorta during a scientific presentation on Tuesday, Nov. 17, at 7:32 a.m. The discussion will include experience from Gore's ARISE Pivotal Trials evaluating the investigational GORE^® Ascending Stent Graft.

Gore's medical business

Gore's medical business develops vascular, cardiac and surgical solutions designed to address complex clinical challenges. For more than 50 years, Gore has applied materials science and engineering expertise to help clinicians improve patient care. With over 3,100 proprietary innovations and more than 55 million implants worldwide, Gore continues to invest in research, clinical evidence and technologies to help shape the future of patient care. Learn more at goremedical.com.

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world's highest peaks to the inner workings of the human body. With approximately 12,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $5.6 billion. gore.com

About VEITHsymposium

Now in its 53rd year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. To register to attend VEITHsymposium, please visit www.VEITHsymposium.org or contact Pauline T. Mayer, Public Relations for VEITHsymposium at 631.807.6335.

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. R_XOnly 

INDICATIONS FOR USE IN THE U.S.: The GORE^® VIABAHN^® VBX Balloon Expandable Endoprosthesis is indicated for the treatment of de novo or restenotic lesions found in iliac arteries with reference vessel diameters ranging from 5 mm - 13 mm and lesion lengths up to 110 mm, including lesions at the aortic bifurcation.

The GORE^® VIABAHN^® VBX Balloon Expandable Endoprosthesis is indicated to maintain visceral artery perfusion as a bridging stent in:

• fenestrated endovascular aortic aneurysm repair with 6-8 mm diameter fenestrations
• branched endovascular aortic aneurysm repair with 6-8 mm diameter branches (e.g. portals, cuffs, or directional branches) that are at least 10 mm in length.

Bridging stent use is limited to aortic endovascular graft systems wherein safety and effectiveness has been demonstrated.

CONTRAINDICATIONS: Do not use the GORE^® VIABAHN^® VBX Balloon Expandable Endoprosthesis in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. Patients with known sensitivities or allergies to the GORE^® VIABAHN^® VBX Balloon Expandable Endoprosthesis materials including expanded polytetrafluoroethylene (ePTFE), fluorinated ethylene propylene (FEP), stainless steel, and heparin.

INDICATIONS FOR USE IN THE U.S.: The GORE^® VIABAHN^® FORTEGRA Venous Stent is indicated for use in the treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction.

CONTRAINDICATIONS: The GORE^® VIABAHN^® FORTEGRA Venous Stent is contraindicated for use in patients with lesions where expansion of an angioplasty balloon catheter to minimum GORE^® VIABAHN^® FORTEGRA Venous Stent recommended vessel diameters was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system.

INDICATIONS FOR USE IN THE U.S.: The GORE^® EXCLUDER^® Thoracoabdominal Branch Endoprosthesis is indicated for endovascular repair in patients with thoracoabdominal aortic aneurysms and high-surgical risk patients with pararenal aortic aneurysms who have appropriate anatomy as described below: Adequate iliac/femoral access and brachial/axillary access; proximal (supraceliac) aortic neck treatment diameter range over 2 cm seal zone of 22-34 mm for aneurysms extending up to 6.5 cm or less above the origin of the most proximal branch vessel; aortic neck angle ≤ 60° at the Aortic Component proximal seal zone; iliac artery treatment diameter range of 8-25 mm and iliac artery seal zone length of at least 10 mm; renal artery seal zone diameters between 4.0-10.0 mm; celiac and superior mesenteric artery seal zone diameters between 5.0-12.0 mm; ≥ 15 mm seal zone length in renal arteries, superior mesenteric artery and celiac artery; and visceral segment of aorta (3 cm proximal through 9.5 cm distal to the most proximal visceral artery) must be ≥ 20 mm in diameter.

CONTRAINDICATIONS: The GORE^® EXCLUDER^® Thoracoabdominal Branch Endoprosthesis is contraindicated in: Patients with known sensitivities or allergies to the TAMBE materials including ePTFE, FEP, nickel titanium alloy (Nitinol), stainless steel and gold. Patients who have a condition that threatens to infect the graft. Patients with known hypersensitivity to heparin, including patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II and cannot receive the GORE^® VIABAHN^® VBX Balloon Expandable Endoprosthesis. 

INDICATIONS FOR USE IN THE U.S.: The GORE^® TAG^® Thoracic Branch Endoprosthesis is indicated for endovascular repair of lesions of the aortic arch and descending thoracic aorta, while maintaining flow into a single aortic arch branch vessel in patients who have: Adequate iliac/femoral access; Proximal Aortic Landing Zones: For Isolated Lesion Patients: Proximal landing zone cannot be aneurysmal, dissected, heavily calcified or heavily thrombosed; For Dissection Patients: Primary entry tear must be distal to the target branch vessel and the proximal extent of the landing zone must not be dissected; Aortic inner diameter range 16-42 mm; Proximal segment length (length from distal edge of target branch vessel to the midpoint of any proximal branch vessel) of at least 2.0-4.0 cm, depending on Aortic Component selection; Proximal covered length (measured from distal edge of target branch vessel to the distal edge of any proximal branch vessel) of at least 15–36 mm, depending on Aortic Component selection; For patients with prior ascending aorta or aortic arch repair with surgical graft: at least 2 cm landing zone proximal to the distal anastomosis; Target Branch Vessel Landing Zone: Landing zone cannot be aneurysmal, dissected, heavily thrombosed and severely tortuous (180 degree turn within the treated length); Target branch vessel inner diameter of 6–18 mm, depending on Side Branch Portal diameter selected; Target branch vessel minimum length of 2.5–3.0 cm, depending on Side Branch Portal diameter selected. Distal Landing Zone (Isolated Lesion Patients only): Outer curve length must be ≥ 2 cm proximal to celiac artery; Aortic inner diameter range 16-42 mm; Cannot be aneurysmal, dissected, heavily calcified or heavily thrombosed; Native Aorta or previously placed GORE^® TAG^® Conformable Thoracic Stent Graft. 

CONTRAINDICATIONS: The GORE^® TAG^® Thoracic Branch Endoprosthesis is contraindicated in: Patients with known sensitivities or allergies to the device materials [ePTFE (polytetrafluoroethylene), FEP (fluoroethylpropylene), Nitinol (nickel, titanium), Gold, SB Component only - Heparin (CBAS^® Heparin Surface)]; Patients who have a condition that threatens to infect the graft; Patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. 

INDICATIONS FOR USE IN THE U.S.: The steerable guiding sheath (GORE^® GUIDRA Steerable Sheath) is intended for the introduction of diagnostic and therapeutic devices into the human vasculature, including but not limited to intracardiac, renal or other peripheral placements. Do not use this device for neural placements.

CONTRAINDICATIONS: The steerable guiding sheath (GORE^® GUIDRA Steerable Sheath) is contraindicated in: Active systemic or local infection, inability to obtain vascular access, patients with atrial thrombus or myxoma, or interatrial baffle or patch, and patients with obstructed or inadequate vasculature.

26PL1289-EN02

MAT-1551-2

SOURCE W. L. Gore & Associates, Inc. MPD Division